Dental Soft Tissue Regeneration Market Report Suite | Europe | 2020-2026 | MedCore
|出版商||iData Research Inc.||商品編碼||953937|
|出版日期||內容資訊||英文 40 Pages
|歐洲的牙科用軟組織再生市場(2020年∼2026年): MedCore Dental Soft Tissue Regeneration Market Report Suite | Europe | 2020-2026 | MedCore|
|出版日期: 2020年06月26日||內容資訊: 英文 40 Pages||
The EU dental soft tissue regeneration market was valued at €7.3 million in 2019. The market value is expected to increase and reach somewhere in between €8.5 and €9.9 million by 2026, depending on the impact of COVID19 on the overall market.
The vast majority of unit sales were xenograft products produced by Geistlich and Botiss, and the remainder consisted mostly of AlloDerm®, which is distributed by BioHorizons. Even if regulations surrounding the use of human tissue for soft tissue regeneration impede sales of these types of products throughout Europe, within the dental indication specifically, the regulatory hurdles are slightly less pronounced.
Some dentists in this market are using these devices to increase biotype and soft tissue thickness around implants. The number of dental regenerative matrix units sold is partly correlated with the number of dental implant procedures in a given country. This explains why, population differences aside, unit sales in Germany and Italy were slightly higher than in France, and significantly higher than in the United Kingdom.
The market for dental soft tissue regeneration consists of xenografts and allografts. Dentists mostly use soft tissue regenerative products for root coverage and ridge augmentation. Compared to other soft tissue reinforcement and regeneration markets, such as breast reconstruction and hernia repair, dental regenerative biologic matrices have not been on the European market for very long.